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Pegylated interferon lambda-1a (Lambda) is currently in clinical development for the treatment of
chronic hepatitis C virus (HCV) infection. To gain insight into the potential mechanisms of non-
responsiveness that may occur in patients treated with Lambda, HCV subgenomic replicon cell-lines
with impaired susceptibility to the unpegylated recombinant (r) form of interferon (IFN) lambda-1
(rIFNλ) were isolated and characterized. The selected replicon cell populations showed a defect in the
activation of the IFN-dependent JAK-STAT signaling pathway. Reduced phosphorylation of STAT proteins
and lower expression levels of the cellular janus kinases Jak1 and Tyk2 were observed in these cell
populations, which may account for the impaired JAK-STAT signaling and reduced antiviral responses to
rIFNλ. Overall, this in vitro study provides molecular insights into the possible mechanism of viral
evasion to rIFNλ in the HCV replicon cell system.
Published by Elsevier Inc.Introduction
Hepatitis C virus (HCV) is a major etiologic agent of liver
disease, afﬂicting an estimated 170 million people worldwide
and resulting in approximately 350,000 deaths annually (World-
Health-Organization, 2011). Over the last decade, a combined
regimen of pegylated interferon alfa (alfa) and ribavirin (RBV)
has been the backbone of therapy for the management of chronic
HCV infection. Unfortunately, a signiﬁcant proportion of patients
fail to respond or relapse after cessation of treatment. Genetic
variations and viral determinants are believed to inﬂuence the
outcome of infection, and different HCV genotypes have been
associated with variable responses to alfa-RBV regimens (Fried
et al., 2002; Ghany et al., 2009; Hayes et al., 2012). Sustained
virologic response (SVR) is achieved in 40–50% of patients infected
with the most predominant HCV genotype (GT) 1 (subtypes 1a and
1b), whereas higher SVR rates (78–86%) have been reported in
patients infected with HCV GT2 and GT3. The recent introduction
of direct acting antiviral (DAA) agents targeting the HCV NS3
protease has dramatically improved SVR rates and shortened
treatment durations, particularly for patients infected with GT1,
(Ghany et al., 2011) Inclusion of either NS3 protease inhibitorsInc.
Myers Squibb Research and
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org),
om (C. Chen),(NS3 PIs) boceprevir or telaprevir to the alfa-RBV regimen has
resulted in 70–75% SVR rates in previously untreated GT1 patients
(Poordad et al., 2011; Jacobson et al., 2011). However, non-
responsiveness to alfa continues to be a substantial hurdle to
more effective and tolerable IFN-based therapies.
Human IFN lambda-1 (IFNλ1), also known as interleukin-29
(IL-29), IFNλ2 (IL-28A) and IFNλ3 (IL-28B) are newly described
type III IFNs which have a close evolutionary relationship to the
interleukin-10 (IL-10) cytokine family, and are distantly related to
the type I IFNs (Kotenko et al., 2003). The biological characteristics
of these cytokines are comparable to those of a type I IFN, such as
IFN-alpha (IFNα) and IFN-beta (IFNβ), although there is limited
sequence homology (Donnelly and Kotenko, 2010). Similar to
IFNα/β, expression of IFNλ1 is induced upon viral infection, and
has demonstrated broad antiviral activity in numerous HCV
replication cell-based models (Marcello et al., 2006; Marukian
et al., 2011; Friborg et al., 2013). These various classes of IFN exert
their antiviral activities by inducing the expression of IFN-
stimulated genes (ISGs). Signal transduction through engagement
of distinct heterodimeric receptor complexes lead to common
activation of the janus kinases, Jak1 and Tyk2, and subsequent
phosphorylation of the signal transducer and activator of tran-
scription (STAT) factors, STAT1 and STAT2. In the type I IFNα
receptor (R) complex, the IFNAR1 and IFNAR2 chains contribute to
ligand binding and activation of Tyk2 and Jak1, respectively.
Conversely, type III IFNs receptor complex composed of the
ubiquitously expressed IL-10Rβ chain (also called IL-10R2) and
the unique IL-28Rα chain play comparable roles to the IFNα co-
receptor subunits IFNAR1 and IFNAR2. Activated STAT1 and STAT2
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stimulated gene factor 3 (ISGF3) complex competent for nuclear
translocation and subsequent binding to the IFN-stimulated
response element (ISRE) located upstream of various ISGs. The
complete spectrum of ISGs that mediate an antiviral effect on HCV
replication has not yet been deﬁned (Schoggins et al., 2011).
Given the comparable biological properties of these two
families of cytokines, it is important to understand whether type
III IFNs could provide an alternative treatment option to alfa with
improved SVR rates. To this end, the investigational pegylated
form of IFNλ1 (Lambda), has demonstrated efﬁcacy in subjects
infected with HCV GT1 through GT4 (Zeuzem et al., 2011, 2012).
Data from a Phase 2b clinical study indicated that SVR rates at 24
weeks after completing treatment were comparable for Lambda-
RBV and alfa-RBV in previously untreated patients with HCV GT1
or GT4 (Muir et al., 2012). However, the Lambda regimen produced
a more rapid decline in HCV RNA through 12 weeks of treatment
compared to the alfa regimen. Thus, a better understanding of the
contrasting responses associated with Lambda would undoubtfully
help in improving outcomes of IFN-based therapy.
The precise mechanisms underlying treatment failure and
limited responsiveness to alfa-based therapy are not fully under-
stood, but various reports have implicated the contribution of
multiple host and viral factors. Asselah et al. (2010) Fundamental
in vitro insights into mechanisms of resistance to IFNα have been
established on studies performed in the HCV replicon system
(Namba et al., 2004; Hazari et al., 2007; Noguchi et al., 2008; Datta
et al., 2011). This human hepatoma cell-culture model carrying
self-replicating HCV subgenomic RNAs representing various GTs
has provided a powerful tool for identifying novel classes of HCV
inhibitors, as well as being useful in understanding their resistance
development proﬁles (Gao et al., 2010; McPhee et al., 2012b).
Consequently, studies described in this report were initiated to
investigate the potential of HCV resistance to rIFNλ in vitro using
the replicon cell system, and to deﬁne its underlying molecular
basis. Overall, our results suggest that a defect in the JAK-STAT
signaling pathway blocks the IFN-induced gene activation, causing
decreased susceptibility to rIFNλ in the HCV replicon cell-based
model.Results
Generation of IFN-resistant HCV replicon cell lines
The HCV replicon cell-based system is a useful tool for
characterizing resistance to antiviral replication inhibitors and
has so far been predictive of the emergence of resistance variants
to DAA in clinical development. Indeed, non-clinical studies haveTable 1
Antiviral activity of HCV replication inhibitors against GT1a WT and NS3-R155K replico
Cell line (GT1a) Compound EC50 (fold resistancea)
ASV (μM)
WT control 0.00570.001
WT IFNr (30 ) 0.00770.001 (1)
WT IFNλr (30 ) 0.00570.001 (1)
NS3-R155K control 0.54670.061
NS3-R155K IFNαr (30 ) 0.40170.096 (1)
NS3-R155K IFNλr (30 ) 0.46670.096 (1)
NS3-R155K IFNλr (100 ) 0.35670.063 (1)
Values are the average7standard deviation from ≥3 independent experiments.
ASV¼asunaprevir; 1453¼BVDV speciﬁc inhibitor.
a Fold over parental control cells is calculated from individual experiments and repdocumented the emergence of several amino acid substitutions in
the NS3 protease region using various HCV replicon cell-based
models. One of these variants is R155K and has been associated
with resistance to the recently approved NS3 PIs boceprevir and
telaprevir in patients failing treatment (Bartels et al., 2008; Susser
et al., 2011). Therefore, to investigate the molecular mechanisms
underlying resistance to Lambda treatment, HCV subgenomic
replicon cell lines representing a wild-type (WT) GT1a or a GT1a
variant encoding R155K in the NS3 domain were maintained in
parallel under selective pressure with either rIFNα or rIFNλ at 30-
or 100-times their EC50 values, and in the presence of G418. Low
multiple EC50 values were applied for long-term treatment to
speciﬁcally avoid curing of the cells from the HCV replicon, as
previously reported (Lemm et al., 2005). These HCV replicons
contain an in-frame gene encoding the neomycin phosphotrans-
ferase (neoR) gene conferring resistance to G418. Replicons that
are not capable of replication under speciﬁc compound inhibitory
pressure will not retain their capacity to rescue host cell viability
through neomycin resistance. Accordingly, visual inspection of the
cultures under IFN selective pressure indicated reduced growth
rates and widespread cell death during the ﬁrst week of treatment.
Following prolonged passages (460 days) under selective pres-
sure in the presence of G418, cells emerged from the initial dying
population indicating the presence of HCV replicons that were
refractory to IFN inhibition. In the GT1a selection, cell cultures
exposed to 100 times EC50 multiples of test compounds showed
signiﬁcant growth impairment and they were therefore excluded
from further analysis. Breakthrough GT1a IFN-resistant cell popu-
lations selected using 30 times EC50 multiples of test compounds
were phenotyped for their susceptibility to various classes of HCV
replication inhibitors. As shown in Table 1, the GT1a replicon cell
population exposed to rIFNλ exhibited reduced susceptibility to
the cytokine (6-fold over WT control level), while retaining
sensitivity to the inhibitory effects of rIFNα. In contrast, GT1a
replicon cells selected in the presence of rIFNα showed reduced
susceptibility to both rIFNα (3-fold) and rIFNλ (6-fold) relative to
the parental control cells. Fold resistance was greater in the GT1a
NS3-R155K replicon cells selected in the presence of 30 times EC50
multiples of rIFNα. Indeed, the NS3-R155K breakthrough IFNα-
resistant replicon cell population demonstrated 6- and 12-fold
reduced susceptibility to rIFNα and rIFNλ, respectively, relative to
the parental control cells. The NS3-R155K breakthrough IFNλ-
resistant cell populations selected at 30 and 100 times the IFNλ
EC50 values, conferred higher resistance to rIFNλ (7- and 19-fold,
respectively) while having low levels of resistance to rIFNα
(4-fold). More importantly, all IFNλ-resistant cell lines tested
retained susceptibility towards the HCV NS3 PI asunaprevir
relative to parental control replicon cell lines suggesting that the
resistance phenotypes were speciﬁc to IFN treatments (Table 1).ns selected during treatment with rIFNα or rIFNλ.
1453 (μM) rIFNα (IU/ml) rIFNλ (ng/ml)
45 5175 3.870.3
45 140717 (3) 2177 (6)
45 73724 (1) 23172 (6)
45 7778 4.870.9
45 469716 (6) 58728 (12)
45 333746 (4) 34712 (7)
45 355763 (4) 95735 (19)
orted as an average.
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J. Friborg et al. / Virology 444 (2013) 384–393386To determine whether amino acid substitutions in the HCV
replicon genome were responsible for the IFN-resistance pheno-
types, genotypic sequencing analysis of the selected replicon cell
populations was performed and compared to their respective
parental control cell lines. Total RNA was extracted and cDNA
subjected to population sequencing over the entire coding region
of the HCV replicon genome. As summarized in Table 2, none of
the replicon cell lines selected under rIFNλ pressure showed
identical genomic sequences with multiple point mutations emer-
ging throughout the NS3, NS5A and NS5B coding regions of the
various HCV genomes. None of the mutation sites overlapped with
a region in NS5A (encompassing amino acids 237–276) referred to
as the IFN sensitivity determining region (ISDR). HCV variants with
mutations in this putative ISDR central region of NS5A were
previously reported to inﬂuence the outcome of IFN therapy,
suggesting a role for the HCV protein in IFN resistance
(Nakagawa et al., 2010; Tran et al., 2011). No amino acid substitu-
tions were identiﬁed in the NS4A and NS4B coding regions of the
various IFN-resistant replicon cell lines. Taken together, our initial
ﬁndings suggest that HCV viral factors are not involved in the
mechanism of IFNλ resistance in these replicon cells.
Susceptibility proﬁles against bovine viral diarrhea virus replication
in IFN-resistant replicon cells
To further investigate the contribution of viral factors in the
mechanisms of rIFNλ resistance, susceptibility proﬁles to IFN
treatment were evaluated against the related but genotypically
distinct BVDV replicon (O’Boyle et al., 2005). Replication of a BVDV
replicon carrying an in-frame ﬁreﬂy luciferase gene was monitored
in the GT1a NS3-R155K IFNλ-resistant replicon cell population. As
shown in Table 3, replication of the BVDV replicon transiently
expressed in the sensitive and IFN-resistant replicon cell lines was
equally suppressed by a selective BVDV inhibitor, compound
1453 (Sun et al., 2003). Accordingly, asunaprevir was inactive
(EC5045 μM) against replication of the BVDV replicon in cells.
In contrast, loss of potency to both rIFNα and rIFNλ against
replication of BVDV replicon was signiﬁcant in the IFNα-resistant
cell lines (14-fold and 8-fold over parental control cells, respec-
tively). As seen during the HCV phenotypic proﬁling, cells selected
in the presence of rIFNλ were 11- to 12-fold less susceptible to this
cytokine while demonstrating only modest 4- to 5-fold losses in
potency to rIFNα, suggesting reduced cross-resistance to this
treatment. The similarity in the resistance phenotypic proﬁles
against HCV replication or BVDV replication in these IFN-selected
replicon cell populations strongly suggest that a common defect in
host-related pathways is responsible for the decreased suscept-
ibilities reported against rIFNα and rIFNλ, rather than selection of
viral drug-resistant variants.
Reduced ISRE signaling in IFN-resistant replicon cell lines
To understand the signiﬁcance of the reduced susceptibility
phenotypes, we next performed studies to determine the func-
tionality of the JAK-STAT signaling pathway in these IFN-resistant
cell populations. Activation of the IFN-mediated signaling pathway
in replicon cells was monitored using a luciferase-based reporter
construct under the control of the ISRE promoter. Cells transiently
expressing the ISRE-luciferase reporter construct were exposed
to various concentrations of rIFNα (1–5000 IU/ml) or rIFNλ
(1–2500 ng/ml) for 24 h. Luciferase activity was then measured
in these cell lysates and results expressed as fold activation over
untreated cells. As shown in Fig. 1, the levels of ISRE-promoter
activation for the different IFNα- and IFNλ-resistant cell popula-
tions correlated with the IFN susceptibility proﬁles. Reduced
activation of the ISRE-promoter in the NS3-R155K IFNα-resistant
Table 3
Antiviral activity of rIFNλ against bovine viral diarrhea virus (BVDV) replicon transiently replicating in the IFN-resistant HCV cell lines.
Cell line (GT1a) Compound EC50 (fold resistancea)
ASV (μM) 1453 (μM) rIFNα (IU/ml) rIFNλ (ng/ml)
NS3-R155K control 45 0.09170.012 1675 2.070.8
NS3-R155K IFNαr (30 ) 45 0.10470.013 (1) 219766 (14) 1576 (8)
NS3-R155K IFNλr (30 ) 45 0.07470.017 (1) 85746 (5) 23710 (12)
NS3-R155K IFNλr (100 ) 45 0.09270.042 (1) 62710 (4) 2275 (11)
Values are the average7standard deviation from ≥3 independent experiments
ASV¼asunaprevir; 1453¼BVDV speciﬁc inhibitor
a Fold over parental control cells is calculated from individual experiments and reported as an average.
Fig. 1. Stimulation of the IFN signaling pathway in GT1a NS3-R155K replicon cell lines sensitive and resistant to rIFNλ. GT1a NS3-R155K IFNα (A) and GT1a NS3-R155K IFNλ
(B) resistant cell lines were transfected with the pISRE-Luc reporter plasmid, and induction proﬁles compared in parallel to the sensitive parental cell line. The activation of
the ISRE promoter in the sensitive ( ) and IFNα ( ) or IFNλ ( ) resistant replicon cell lines was determined in the presence or absence of increasing concentrations of
rIFNα (1–5000 IU/ml) or rIFNλ (1–2500 ng/ml) 24 h following stimulation. Fold activation values represent the average from ≥3 independent experiments.
J. Friborg et al. / Virology 444 (2013) 384–393 387cell line was observed upon stimulation with either rIFNα or rIFNλ
when compared to the control parental cell line (Fig. 1A). Reduc-
tions of approximately 50% in ISRE-luciferase activities were noted
at all doses tested in the NS3-R155K IFNα-resistant cell line. In
contrast, the NS3-R155K rIFNλ-resistant cell line exhibited reduced
ISRE-promoter activation solely upon rIFNλ stimulation when
compared to the control parental cell line (Fig. 1B). This reﬂects
the lack of cross-resistance to rIFNα in the IFNλ-resistant cell
populations, as reported in our replicon susceptibility assays.
Similar ISRE-promoter activation proﬁles were noted in the GT1a
IFNα- and IFNλ-resistant cell lines (see Fig. S1 in the supplemental
material). These ﬁndings suggest that a defect up-stream of the
cellular JAK-STAT signaling pathway may be responsible for the
observed IFN-resistant phenotypes in replicon cells.
Defective JAK-STAT signaling pathway in IFN-resistant replicon cells
To gain insights into the mechanisms of the defective IFN
signaling in the resistant replicon cell lines, expression levels of
various cellular components involved in the JAK-STAT pathway
were monitored upon stimulation with rIFNα or rIFNλ and com-
pared to the control parental cell line. GT1a NS3-R155K sensitiveand resistant replicon cell populations were exposed to rIFNα or
rIFNλ at different concentrations, and cell lysates harvested fol-
lowing 30 min stimulation. Equal amounts of protein extracts
were subjected to Western immunoblot analysis using antibodies
directed against the phosphorylated or un-phosphorylated forms
of STAT1 (Fig. 2). Results from this experiment revealed that the
levels of phosphorylated STAT1 in the rIFNα-resistant cell line
were lower following stimulation with either rIFNα (Fig. 2A) or
rIFNλ (Fig. 2B) when compared to the control parental cell line. In
contrast, phosphorylation of STAT1 in the rIFNλ-resistant cell line
was attenuated only upon stimulation with rIFNλ and not affected
with rIFNα. Similar proﬁles were obtained when assessing phos-
phorylation of STAT2 in these replicon cell lines (see Fig. S2 in the
supplemental material). Expression levels of total STAT1 and
STAT2 proteins were comparable between sensitive and IFN-
resistant replicon cell populations. This analysis supports the lack
of cross-resistance to rIFNα in these cells, and is in agreement with
results reported from the ISRE promoter activation assays.
Interferon treatment leads to the activation of the janus kinases
Jak1 and Tyk2, which are responsible for the down-stream
phosphorylation event of STAT molecules. Therefore, we next
evaluated the total protein expression of these kinases in the
Fig. 2. Western immunoblot analysis of STAT1 phosphorylation in IFN-sensitive and -resistant replicon cell lines. Phosphorylation status of STAT1 (pSTAT1) in IFN-sensitive
and -resistant GT1a NS3-R155K replicon cell lines was monitored by Western immunoblotting using an antibody directed against the phosphorylation form of the protein.
Each cell line was exposed to increasing concentrations of rIFNα (A) or rIFNλ (B) for 30 min. Cell lysates were prepared and equal amounts of proteins were used to examine
the levels of STAT1 phosphorylation. Relative intensity of pSTAT1 detected in IFN-sensitive (close circle) and -resistant GT1a NS3-R155K replicon cell lines (rIFNα, open
square; rIFNλ, open triangle) was quantiﬁed and plotted on the right graphs. Data are representative of 3 independent Western immunoblot analyses.
Fig. 3. Levels of endogenous Jak1 and Tyk2 in IFN-sensitive and -resistant replicon cell lines. Expression of the IFN signaling components Jak1 and Tyk2 was monitored in the
GT1a NS3-R155K replicon cell lines sensitive or resistant to IFN treatments by Western immunoblotting using antibodies directed against each kinases. An antibody to
β-actin was used as loading control to ensure an equivalent amount of protein extracts analyzed among samples. Each cell line was exposed to rIFNα (A) or rIFNλ (B) for
30 min. Cell lysates were prepared and equal amounts of proteins were used to examine the levels of Jak1 or Tyk2. All replicon cell lines resistant to rIFNα or rIFNλ
demonstrated reduced expression of Tyk2 relative to the control parental cell line.
J. Friborg et al. / Virology 444 (2013) 384–393388rIFNα- and rIFNλ-resistant cell lines (Fig. 3). Results from the
Western immunoblot analysis indicated that both IFNα- and
IFNλ-resistant replicon cell lines have reduced expression of
Tyk2 as compared to the control parental cell line. The expression
of Jak1 was also reduced in the IFNλ-resistant cell population,
while not being affected in the IFNα-resistant cell population when
compared to the control parental cell line.
Tyk2 was previously shown to stabilize the cell surface expres-
sion of IFNAR1 by decreasing its basal internalization rate
(Ragimbeau et al., 2003; Marijanovic et al., 2006). In the absence
of Tyk2, IFNAR1 localized primarily into perinuclear endosomal
compartments, potential sites of proteolysis. To assess whether the
reduced expression of Tyk2 noted in the IFN-resistant replicon
cells inﬂuenced the localization of IFNAR1, indirect immunoﬂuor-
escence staining analysis was performed in these cells (Fig. 4). As
previously reported (Ragimbeau et al., 2001), abundant distribu-
tion of Tyk2 was observed in both the cytoplasmic and the nuclear
compartments of the parental IFN-sensitive cell line (panel a). Inaccordance, staining of the IFNAR1 in those cells revealed both a
cytoplasmic and plasma membrane distribution (panels d and g).
Conversely, the intracellular staining of Tyk2 was very weak in
both IFN-resistance replicon cell population (panels b and c).
Expression of IFNAR1 in the IFNα-resistant cell population was
found to be localized in the perinuclear endosomal compartment
(panels e and h). On the other hand, IFNAR1 staining in the
IFNλ-resistant cell populations was predominantly localized in
the perinuclear space (panels f and i). In the IFNλ heterodimeric
receptor complex, Tyk2 interacts with the IL-10Rβ chain. However,
little is known about the effect of Tyk2 on the cellular distribution
of IL-10Rβ. Staining of IL-10Rβ in the sensitive parental cell line
revealed a punctuate cytoplasmic distribution (panels j and m).
A similar cellular pattern was detected in the IFNα-resistant cell
population. In contrast, a dense perinuclear punctuate IL-10Rβ
staining was noted in the IFNλ-resistant cell population (panels l
and o). The overall protein synthesis of cognate subunits of IFNα
and IFNλ receptor complexes was not affected in the resistant cell
Fig. 4. Reduced expression of Tyk2 alters subcellular localization of IFNAR1 in IFN-resistant replicon cells. Distribution of Tyk2, IFNAR1 and IL-10Rβ was monitored by
ﬂuorescence microscopy in the GT1a NS3-R155K replicon cell lines that were sensitive or resistant to IFN treatments. Cells were ﬁxed, permealized and stained with an
antibody to Tyk2, IFNAR1, or IL-10Rβ, followed by (red) Alexa Fluor 594- and (green) Alexa Fluor 488-coupled secondary antibodies, respectively. Nuclei were counterstained
with (blue) Hoeschst dye as shown in the overlays (panels: a–c, g–i and m–o).
Table 4
Overview of genes up-regulated following induction by rIFNα or rIFNλ in IFN-resistant GT1a replicon cell lines.
Gene ID Gene
symbol
Description NS3-R155K NS3-R155K IFNαr NS3-R155K IFNλr
rIFNα afold
increase
rIFNλ afold
increase
rIFNα afold
increase
rIFNλ afold
increase
rIFNα afold
increase
rIFNλ afold
increase
NM_002416 CXCL9 Chemokine (C-X-C motif) ligand 9 7.7 7.9 ocutoffb ocutoffb ocutoffb ocutoffb
NM_005101 ISG15 ISG15 ubiquitin-like modiﬁer 40.6 90.8 18.3 22.4 26.2 29.1
NM_002053 GBP1 Guanylate binding protein 1, interferon-
inducible
5.1 12.1 ocutoffb 3.9 ocutoffb 4.1
NM_002198 IRF1 Interferon regulatory factor 1 ocutoffb 4.3 ocutoffb ocutoffb ocutoffb ocutoffb
NM_006084 IRF9 Interferon regulatory factor 9 11.8 14.5 11.7 11.7 9.5 8.1
NM_002229 JUNB Jun B proto-oncogene ocutoffb 3.1 ocutoffb ocutoffb ocutoffb ocutoffb
NM_000625 NOS2 Nitric oxide synthase 2, inducible 3.7 4.8 ocutoffb ocutoffb ocutoffb ocutoffb
NM_002534 OAS1 2′-5′-oligoadenylate synthetase 1, 40/46kDa 7.4 23.6 5.7 9.2 7.1 10.9
NM_007315 STAT1 Signal transducer and activator of
transcription 1, 91kDa
ocutoffb 4.4 ocutoffb ocutoffb ocutoffb ocutoffb
NM_005419 STAT2 Signal transducer and activator of
transcription 2, 113kDa
ocutoffb 3.8 ocutoffb ocutoffb ocutoffb ocutoffb
a Fold decrease in gene expression is calculated for each cell population over control parental GT1a NS3-R155K cell line.
b An arbitrary cutoff of ≥3-fold reduction over baseline was applied.
J. Friborg et al. / Virology 444 (2013) 384–393 389populations as documented by quantitative real-time PCR and
Western immunoblot analysis (see Fig. S3 in the supplemental
material). Taken together, these data suggest that the reduced
Tyk2 expression in cells altered the localization pattern of the
IFNAR1 and IL-10Rβ subunits.
Reduced expression of genes related to the JAK-STAT signaling
pathway in IFN-resistant replicon cells
In light of differences in activation of the JAK-STAT pathway
observed in the IFN-resistant replicon cell populations, expression
of related signal transduction genes was examined using a cDNA
microarray analysis (84 target genes included in the RT2 proﬁler
array). In these experiments, sensitive and resistant replicon cellpopulations were stimulated for 24 h with rIFNα (100 IU/ml) or
rIFNλ (10 ng/ml), while control cells were left untreated. Following
IFN stimulation, total RNA was puriﬁed from cells and gene
expression proﬁling for human JAK-STAT target components was
performed using the RT2 proﬁler PCR arrays. To analyze the direct
effects of IFN resistance, we compared gene expression proﬁles
between the control parental cell line and each of the IFN-resistant
cell populations. As shown in Table 4, 10 genes were up-regulated
(≥3-fold cut-off range) following rIFNλ treatment in the sensitive
GT1a NS3-R155K cell line. These genes included known ISGs and
chemokines induced by STAT1 (CXCL9, GBP1, JUNB, NOS2, ISG15,
OAS1), as well as transcription factors that interact with STAT
proteins (IRF1, IRF9); previously reported to be up-regulated upon
rIFNλ stimulation in HCV replicon models (Marcello et al., 2006).
J. Friborg et al. / Virology 444 (2013) 384–393390There were differences in the number of genes up-regulated and
the magnitude of their stimulation in the rIFNα- and rIFNλ-
resistant cell populations when compared to the sensitive parental
cell line, correlating with a defect in the JAK-STAT signaling
pathway. The gene most strongly induced by both cytokines was
ISG15 which increased by 41-fold and 91-fold in the presence of
rIFNα and rIFNλ, respectively. However, the level of induction of
ISG15 mRNA expression was lower in the rIFNα- (22-fold) and
rIFNλ- (29-fold) resistant cell populations upon rIFNα stimulation.
Expressions of other modulated genes were also markedly reduced
in the IFN-resistant cell populations compared to the IFN-sensitive
parental cell line. These data support the notion that a failure to
activate the JAK-STAT signaling pathway in these cell populations
contributes to the in vitro mechanism of IFNλ resistance.Discussion
The molecular mechanisms underlying variable responses to
alfa treatment remain poorly understood. However, several reports
have suggested that viral and host factors may contribute to the
lack of efﬁcacy to alfa during HCV infection (Asselah et al., 2010;
Doyle et al., 2012). In this report, we utilized the HCV subgenomic
replicon system representing GT1a for the generation and char-
acterization of cells with reduced susceptibility to rIFNλ treatment.
Our overall ﬁndings document for the ﬁrst time that alteration in
the host-related JAK-STAT signaling pathway during long-term
exposure to low doses of rIFNλ may lead to viral evasion.
Phenotypic analysis demonstrated that the susceptibility of the
breakthrough HCV replicons under selective pressure with rIFNλ
signiﬁcantly decreased against this cytokine, while retaining
susceptibility to rIFNα. In contrast, replicon cells selected in the
presence of rIFNα demonstrated reduced susceptibility to both
cytokines relative to parental control cells. Similar phenotypic
proﬁles were noted against a GT1a replicon cell line encoding NS3
protease R155K, a variant that has been shown to confer cross-
resistance to the two NS3 PIs boceprevir and telaprevir. Resistance
proﬁles were speciﬁc to IFN treatments as selected replicon cell
populations and parental cell lines showed comparable suscept-
ibilities to the NS3 PI asunaprevir (Table 1) and the NS5A replica-
tion inhibitor daclatasvir (data not shown). Moreover, sequence
analysis of IFNλ-resistant replicon cell populations failed to iden-
tify common amino acid substitutions in the HCV genome respon-
sible for the resistance phenotypes. Sequence variations within a
discrete region of NS5A deﬁned as the IFN sensitivity determining
region (ISDR) have been associated with negative outcomes to alfa
treatment (Enomoto et al., 1996; Hayashi et al., 2013). However,
conﬂicting results over the years, especially from studies investi-
gating European and North American HCV isolates, have ques-
tioned this correlation (Tan and Katze 2001). Our genotypic
analysis of the selected replicon revealed the emergence of
random point mutations throughout the NS3, NS5A and NS5B
coding regions of the various HCV genomes. None of the mutation
sites overlapped with the NS5A ISDR domain suggesting a lack of
association with the IFN resistance phenotypes described in the
replicon cell populations. More importantly, replication of the
related but genotypically distinct BVDV replicon transduced in
these selected cell populations demonstrated similarly reduced
susceptibilities to rIFNα and rIFNλ inhibition. Based on these
collated data, mechanisms of rIFNλ resistance in these cell popula-
tions appear to involve altered host pathways rather than direct
interactions with viral factors.
To further deﬁne the reduced susceptibility proﬁles established
in the IFN-resistant cell populations, the functionality of the IFN
signaling pathway was investigated next by monitoring the
activation of a reporter luciferase construct driven by the ISREpromoter upstream of IFN responsive genes. All IFNλ-resistant
replicon cell lines had reduced levels of ISRE-promoter activation
in line with their viral phenotypic proﬁles. The IFNα-resistant
replicon cell populations showed reduced ISRE-driven luciferase
activity after stimulation with rIFNα or rIFNλ when compared to the
parental control cell lines. In contrast, minimal cross-resistance to
rIFNαwas noted in the IFNλ-resistant replicon cell population which
corroborated with the viral phenotypic proﬁle. These disparate
cross-resistance proﬁles are intriguing in light of studies document-
ing the establishment of a refractory state of the IFN transduction
pathway in various cell lines and in mice upon repeated stimulation
with rIFNα (Sarasin-Filipowicz et al., 2009; Makowska et al., 2011).
Desensitization appears to target IFNα through the mediated inter-
action of the ISG-encoded ubiquitin-speciﬁc peptidase 18 (USP18)
with the cognate receptor subunit IFNAR2 (Sarasin-Filipowicz et al.,
2009; Francois-Newton et al., 2011). In contrast, IFNβ and IFNλ were
shown to be unaffected by repeated stimulation of the IFN transduc-
tion pathway (Makowska et al., 2011). Thus, even though both IFNα
and IFNλ act through a common JAK-STAT pathway, they appear to
be governed by differential regulatory control mechanisms. Further
experiments will be required to address the impact of USP18
expression on the IFNλ signaling pathway.
Previous reports have suggested that NS5A plays an important
role in the regulation of IFN signaling by interacting directly with
STAT1 and inhibiting its phosphorylation (Lan et al., 2007;
Kumthip et al., 2012). Herein, resistance phenotype proﬁles were
associated with reduced phosphorylation levels of both STAT1 and
STAT2, once again underlying a general alteration in the host
pathway of our replicon cell lines. Hence, this defect in IFN
signaling may be a functional consequence of reduced expression
of the upstream cellular mediator components of the JAK-STAT
pathway. To support this assumption, it was found that IFNλ-
resistant cell populations have reduced expression of the janus
kinases Jak1 and Tyk2. In line with these observations, several
studies have reported the establishment of IFNα-resistant replicon
cell lines with a defect in the JAK-STAT signaling (Hazari et al.,
2007; Zhu et al., 2005). In agreement with our results, Hazari et al.
(2007). demonstrated that the resistant phenotype associated with
IFNα results from reduced expression of Jak1 and Tyk2, ultimately
leading to defective phosphorylation of STAT proteins in replicon
cells. It is therefore not surprising that IFNλ would follow a similar
path of resistance development since both types of cytokines
signal through the JAK-STAT pathway in order to induce their
overlapping biological activities. Furthermore, our immunoﬂuor-
escence analysis revealed an alteration in the subcellular distribu-
tion of the IFNAR1 chain and the IL-10Rβ chain in the IFN-resistant
cell populations (Fig. 4). In the case of the type I IFN, a direct
interplay between Tyk2 and the short-lived IFNAR1 protein has
been shown to inﬂuence the localization and proteolysis fate of
this co-receptor subunit, in turn regulating responses to IFNα
(Ragimbeau et al., 2003; Marijanovic et al., 2006). Subsequently,
functional disruption of the IFNAR1 was shown to play an
important role in resistance to IFNα in replicon cells (Datta et al.,
2011; Naka et al., 2005). Although the afﬁnity of IFNAR1 for IFNα is
weak, its tethering is crucial for the efﬁcient assembly and
functional stability of the ternary ligand-receptor complex. Cur-
rent knowledge regarding the IL-10Rβ function in the IFNλ
receptor complex is limited to recruitment and binding to Tyk2.
With other IL-10 related cytokines, downstream signaling events
upon ligand stimulation are not dependent on IL-10Rβ but rather
on their respective co-receptor chains (Donnelly et al., 2004;
Sheikh et al., 2004). Unfortunately, the lack of reliable staining
antibodies for the detection of the IL-28Rα co-receptor protein in
conjunction with its putative low expression has hampered
immunoﬂuorescence studies of subcellular distribution. Therefore,
we cannot rule out that the reduced expression of Jak1 observed
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effect on the physiological expression of the IFNλ receptor and
ultimately on the downstream JAK-STAT signaling cascade. Unlike
IL-10Rβ, the expression levels of IL-28Rα mRNA have been shown
to vary greatly among tissues and, as a consequence, its expression
is believed to be a limiting factor in the responsiveness to IFNλ
stimulation (Witte et al., 2009). In contrast to the IFNAR2 chain
which is highly expressed in many cell populations, levels of Tyk2
may set a lower sensitivity threshold of the more restrictive
IL-28Rα chain by modulating the surface density of IL-10Rβ
required for proper stability of the IFNλ receptor complex. Further
studies will need to address the dynamics between the janus
kinases and the co-receptor subunits of IFNλ.
Although multiple models for the limited efﬁcacy of alfa
treatment against HCV infection have been proposed, its under-
lying mechanism (s) remains elusive. Ongoing clinical studies have
indicated that Lambda may offer an alternative option for the
treatment of chronic HCV. Regimens that include Lambda have
resulted in more rapid declines in HCV RNA in patients when
compared with alfa-containing regimens, leading to improved
viral response rates at Weeks 4 and 12 of treatment in GT1
through GT4. However, these studies revealed similar SVR rates
for Lambda- and alfa-containing regimens (Zeuzem et al., 2012;
Muir et al., 2012). Therefore, clariﬁcation of non-responsiveness in
these patient populations still requires additional work for future
clinical guidance. Our in vitro data imply that functional cellular
deﬁciencies in the JAK-STAT signaling pathway may provide a
basic platform for understanding Lambda response rates in HCV
patients. The implications of these in vitro results will be explored
further to determine any correlation with in vivo ﬁndings.Materials and methods
Cell lines and compounds
Human hepatoma Huh-7 cells that stably maintain the HCV
subgenomic replicon representing genotype (GT) 1 subtype a
(GT1a) (H77c strain: NCBI reference NC_004102.1) carrying an
in-frame humanized renilla luciferase gene was previously
described (McPhee et al., 2012b). Huh-7 cells that stably maintain
a HCV GT1a subgenomic replicon with a speciﬁc amino acid
substitution at NS3 protease residue R155 (NS3-R155K) was
established following selection in the presence of G418 as pre-
viously described (McPhee et al., 2012b). The bovine viral diarrhea
virus (BVDV) replicon genome carrying an in-frame ﬁreﬂy lucifer-
ase gene was previously described (O’Boyle et al., 2005). The
unpegylated recombinant human IFNα-2b (rIFNα) was purchased
from Myoderm Medical Supply (Norristown, PA). The unpegylated
recombinant human IL-29 (rIFNλ) was synthesized by ZymoGe-
netics, Inc (Seattle, WA). The structures and selective antiviral
properties of the HCV NS3 protease inhibitor (NS3 PI) asunaprevir
(ASV; BMS-650032), and of the BVDV inhibitor, compound 1453,
were previously described (McPhee et al., 2012a, 2012b; Sun et al.,
2003).
Generation of IFN-resistant replicons
To generate stable IFN-resistant cell populations (IFNαr or
IFNλr), GT1a replicon cell lines were maintained in Dulbecco′s
modiﬁed eagle medium (DMEM) supplemented with 10% FBS,
2 mM L-glutamine, 0.5 mg/ml G418, containing various concentra-
tions of rIFNα or rIFNλ, representing 30 or 100 times the 50%
effective concentration (EC50) values determined (rIFNα
EC50¼50 IU/ml; rIFNλ EC50¼2 ng/ml). Cells were passaged at
3–4 day intervals to maintain a sub-conﬂuent monolayer forgreater than 60 days, and IFNs were replenished in fresh media
at the desired concentrations. Each replicon cell line propagated in
parallel in the absence of IFN treatment and served as controls.
The genotype and phenotype of the cell populations selected
under IFN selective pressure were monitored to ensure continuous
replication of the HCV replicon.
Phenotypic analysis
The susceptibility phenotype of the selected replicon cell
populations to different classes of replication inhibitors was
measured using either the intrinsic renilla luciferase activity of
the stable HCV replicon, or the intrinsic ﬁreﬂy luciferase activity of
a BVDV replicon transiently expressed in cells. For HCV phenotypic
proﬁling, replicon cells were incubated for 3 days (37 1C, 5% CO2)
in 96-well black-clear bottom plates (Costar 3614; BD Biosciences,
San Diego, CA) in the presence of 3-fold serial dilutions of test
compound in dimethyl sulfoxide (DMSO) or in Dulbecco′s phos-
phate buffered saline (D-PBS). HCV RNA replication was measured
using a homogenous renilla luciferase substrate (Enduren E6481;
Promega, Madison, WI) according to manufacturer′s instructions.
For transient phenotypic proﬁling, BVDV replicon in vitro RNA
transcript was prepared from Sca I digested plasmid templates
using the T7 RiboMax Express Large Scale Production System
(P1320; Promega, Madison, WI) according to manufacturer′s
instructions. Subsequently, 10 μg of BVDV RNA was electroporated
into HCV replicon cell lines using a Bio-Rad GenePulser system
(Bio-Rad Laboratories, Hercules, CA). Following electroporation,
cells were diluted in DMEM supplemented with 10% FBS and
seeded in 96-well black-clear bottom plates in the presence of
3-fold serial dilutions of test compound in DMSO or in D-PBS for
3 days. Replication of BVDV replicon in cells was measured using
the ﬁreﬂy luciferase assay system (Promega, Madison, WI) accord-
ing to manufacturer′s instructions. The 50% effective concentration
(EC50) values were calculated with XLﬁt software (version 2.0;
IDBusiness Solutions, Burlington, MA) using a 4-parameter logistic
equation: y¼A+([BA]/[1+([C/x]D4)].
Genotyping of IFN-resistant replicons
Total RNA was isolated from selected replicon cell populations
using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA). First
strand cDNA was synthesized from a speciﬁc GT1a primer with
SuperScript II reverse transcriptase reagents (Invitrogen Corpora-
tion, Carlsbad, CA). PCR was then performed with Platinum Taq
high-ﬁdelity DNA polymerase (Invitrogen Corporation, Carlsbad,
CA). The NS3 to NS5B coding region was ampliﬁed with genotype
1a primers; 5′–TGAATGTCGTGAAGGAAGCAG- 3′ (forward) and
5′–GGAGTGTTTACCCCAACCTT-3′ (reverse). Puriﬁed amplicons
were subjected to sequence analysis and alignments were per-
formed using Sequencher software (Gene Codes, Ann Arbor, MI).
IFN-signaling reporter assays
The IFN-mediated regulation of a pISRE-driven luciferase cis-
reporter plasmid (Agilent Technologies, Santa Clara, CA) that
contains ﬁve direct repeats of the ISRE was monitored in the
IFN-resistant replicon cell populations upon stimulation with
rIFNα or rIFNλ. Brieﬂy, cells seeded overnight in DMEM supple-
mented with 10% FBS were transfected with 0.25 μg of the pISRE-
luciferase plasmid using FuGENE 6 transfection reagent (Roche
Diagnostic Corporation, Indianapolis, IND). rIFNα or rIFNλ was
added to the cultures at various concentrations, and cells were
incubated for 24 h at 37 1C in 5% CO2. To measure luciferase
activity, cells were washed with D-PBS, harvested with 1 times
luciferase cell culture lysis buffer and incubated at room
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were then transferred to 96-well solid white plates in triplicate
(OptiPlate 6005290; Perkin-Elmer Life Sciences, Waltham, MA)
and ﬁreﬂy luciferase substrate added to each well. Luminescence
was measured immediately using a TopCount NXT counter.
Western immunoblot analysis
Cell lysates were prepared from replicon cells and the expres-
sion of various JAK-STAT signaling proteins was monitored by
Western immunoblot analysis. Antibodies to Jak1, Tyk2, STAT1,
phospho-STAT1 (Tyr701), phospho-STAT2 (Tyr690) and β-actin
were purchased from Cell Signaling (Beverly, MA). Antibodies to
IFNAR1, IFNAR2 and IL-28Rα were purchased from Lifespan Bios-
ciences (Seattle, WA). IL-10Rβ and STAT2 antibodies were pur-
chased from R&D Systems (Minneapolis, MN) and BD Biosciences
(San Jose, CA), respectively. Brieﬂy, equivalent number of cells
(1105) seeded in 12-well assay plates (Becton Dickinson, Frank-
lin Lakes, NJ) were treated with rIFNα or rIFNλ for 30 min at 37 1C
in 5% CO2. IFN-treated and untreated replicon cells were then
washed once with D-PBS and lysed with 100 μL of RIPA buffer
(SIGMA) supplemented with protease inhibitors and phosphatase
inhibitors cocktails (SIGMA). Equal amounts of protein lysates
were separated by NuPAGE 3-8% gel and then transferred onto
an Invitrolon PVDF membrane (Invitrogen, Carlsbad, CA). The
membrane was incubated with the indicated primary antibody
and subsequently with the appropriate secondary antibody con-
jugated with horseradish peroxidase. Proteins were detected using
the Amersham ECL Plus Western blotting detection system (GE
healthcare, Buckinghamshire, UK) and chemiluminescent signals
were visualized using Kodak BioMax ﬁlm (Carestream health,
Rochester, NY). Relative protein levels detected were quantiﬁed
using Fujiﬁlm MultiGauge software and the arbitrary unit (AU)
reported from the average of three independent analyses.
Fluorescence microscopy analysis
Replicon cells were seeded onto chamber slides (Nalge Nunc
International, Denmark) at a density of 5104 cells per well
overnight then ﬁxed with 4% paraformaldehyde and permealized
prior to antibody staining. Cells were incubated overnight at room
temperature with antibodies to IFNAR1 (Lifespan Biosciences,
Seattle, WA), IL-10 Rβ (R&D Systems, Minneapolis, MN) or to
Tyk2 (Santa Cruz Biotechnology, Santa Cruz, CA). Primary anti-
bodies were subsequently incubated for 1 h at room temperature
with Alexa Fluor488- and Alexa Fluor594-coupled secondary anti-
bodies, respectively, as recommended by the manufacturer′s
instructions (Molecular Probes, Grand Island, NY). Nuclei were
counterstained with Hoeschst dye and cells were visualized under
a Nikon Eclipse TE 300 microscope.
JAK-STAT signaling PCR array analysis
Replicon cells seeded overnight in 6-well assay plates (Becton
Dickinson, Franklin Lakes, NJ) at a density of 1.5105 cells per well
were treated with rIFNα (100 IU/ml) or rIFNλ (10 or 100 ng/ml) for
24 h at 37 1C in 5% CO2. Following IFN stimulation, total RNA was
isolated and puriﬁed from cells using the Qiagen RNeasy kit
(Qiagen, Valencia, CA). Gene expression proﬁling for human JAK-
STAT target genes was performed using RT2 proﬁler PCR arrays
(SABiosciences PAHS-039A, Frederick, MD) following the manu-
facturer′s instructions. Brieﬂy, 1 μg RNA was reverse transcribed
with the RT2 proﬁler PCR array ﬁrst strand synthesis assay
(SABiosciences, Frederick, MD) followed by real-time PCR with
RT2 real-time PCR master mix SYBR green ROX (SABiosciences,
Frederick, MD). Modulation of gene expression in each sample wasanalyzed using the RT2 proﬁler data analysis software 3.4 (SABios-
ciences, Frederick, MD).Acknowledgments
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